CD274 and non-small cell lung carcinoma: However, it remains uncertain whether this association persists in regimens incorporating anlotinib.<h4>Methods</h4>We retrospectively analyzed 77 consecutive patients with advanced NSCLC who received PD-1/PD-L1 inhibitors plus platinum-based chemotherapy with (n = 17) or without (n = 60) anlotinib.